MENLO PARK, Calif., April 03, 2025 (GLOBE NEWSWIRE) — SPARK NS today announced the eight projects and principal investigators selected for the SPARK NS Translational Research Program, 2025 Cohort. Participation in a SPARK NS program cohort lasts two years and includes milestone-based funding of up to $2,000,0001 for each project, education and training in drug development and translational research for participating teams, mentoring from 75+ industry expert advisors, and scientific and business networking opportunities. SPARK NS is dedicated to advancing academic discoveries in Parkinson’s disease and autism around the world from the lab to the clinic.
The eight projects selected for the 2025 Cohort focus on Parkinson’s disease. Combined with the five projects selected for the 2024 Cohort, SPARK NS now has 13 Parkinson’s disease projects based in the US and the UK actively participating in its translational research program and eligible for up to $26 million in aggregate funding. SPARK NS will release a Call for Proposals for the 2026 Cohort of the program in April 2025. For the 2026 Cohort, SPARK NS will accept applications from principal investigators in the US, Canada, UK, and Europe with projects focused on Parkinson’s disease and autism.
Full story: SPARK NS Selects Eight Projects to Receive Aggregate
